Currently, micro dystrophin is the only approved gene therapy for DMD that is theoretically universal, assuming no pre-existing immunity to the AAV serotype used for delivery, as it holds no mutation-specificity (Table 1) [41]. Here, DMD is linked to Duchenne muscular dystrophy.